JAK-STAT Signaling: A Double-Edged Sword of Immune Regulation and Cancer Progression

STAT1 signaling shields T cells from NK cell-mediated cytotoxicity

(2019) Yu Hui Kang et al.   Nature Communications

Therapeutic Implication of SOCS1 Modulation in the Treatment of Autoimmunity and Cancer

(2019) Jatin Sharma et al.   Frontiers in Pharmacology

Fine-Tuning of Type I Interferon Response by STAT3

(2019) Ming-Hsun Tsai et al.   Frontiers in Immunology

Type I interferon suppresses tumor growth through activating the STAT3-granzyme B pathway in tumor-infiltrating cytotoxic T lymphocytes

(2019) Chunwan Lu et al.   Journal for ImmunoTherapy of Cancer

Targeting regulatory T cells by curcumin: A potential for cancer immunotherapy

(2019) Rana Shafabakhsh et al.   PHARMACOLOGICAL RESEARCH

Novel activators and small-molecule inhibitors of STAT3 in cancer

(2019) Lehe Yang et al.   CYTOKINE & GROWTH FACTOR REVIEWS

Myeloid maturation potentiates STAT3-mediated atypical IFN-γ signaling and upregulation of PD-1 ligands in AML and MDS

(2019) Digdem Yoyen-Ermis et al.   Scientific Reports

Interferon-gamma induces autophagy-associated apoptosis through induction of cPLA2-dependent mitochondrial ROS generation in colorectal cancer cells

(2018) Qiu-Shuang Wang et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

SHP-1 acts as a Tumor Suppressor in Hepatocarcinogenesis and HCC Progression

(2018) Liang-Zhi Wen et al.   CANCER RESEARCH

Mutations in the signal transducer and activator of transcription family of genes in cancer

(2018) Nahid Shahmarvand et al.   CANCER SCIENCE

Revisiting Interleukin-12 as a Cancer Immunotherapy Agent

(2018) Pedro Berraondo et al.   CLINICAL CANCER RESEARCH

ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial

(2018) John M Wrangle et al.   LANCET ONCOLOGY

IDO expression in breast cancer: an assessment of 281 primary and metastatic cases with comparison to PD-L1

(2018) Erik A. Dill et al.   MODERN PATHOLOGY

Study on the mechanism of JAK2/STAT3 signaling pathway-mediated inflammatory reaction after cerebral ischemia

(2018) Yuquan Wu et al.   Molecular Medicine Reports

Novel identification of STAT1 as a crucial mediator of ETV6-NTRK3-induced tumorigenesis

(2018) Jinah Park et al.   ONCOGENE

Gene regulation and suppression of type I interferon signaling by STAT3 in diffuse large B cell lymphoma

(2018) Li Lu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

IRF9 and unphosphorylated STAT2 cooperate with NF-κB to drive IL6 expression

(2018) Jing Nan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The revival of CpG oligonucleotide-based cancer immunotherapies

(2018) Tomasz Adamus et al.   Wspolczesna Onkologia-Contemporary Oncology

Curcumin interacts directly with the Cysteine 259 residue of STAT3 and induces apoptosis in H-Ras transformed human mammary epithelial cells

(2018) Young-Il Hahn et al.   Scientific Reports

Prospects of IL-2 in Cancer Immunotherapy

(2018) Hani Choudhry et al.   Biomed Research International

A Positive Feedback Amplifier Circuit That Regulates Interferon (IFN)-Stimulated Gene Expression and Controls Type I and Type II IFN Responses

(2018) Agata Michalska et al.   Frontiers in Immunology

Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion

(2018) Flávia Castro et al.   Frontiers in Immunology

Interleukin-1 Beta—A Friend or Foe in Malignancies?

(2018) Rebekka Bent et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study

(2018) Antoni Ribas et al.   Cancer Discovery

SHP2 inhibition triggers anti-tumor immunity and synergizes with PD-1 blockade

(2018) Mingxia Zhao et al.   Acta Pharmaceutica Sinica B

The significant role of interleukin-6 and its signaling pathway in the immunopathogenesis and treatment of breast cancer

(2018) Ali Masjedi et al.   BIOMEDICINE & PHARMACOTHERAPY

JAK/STAT signaling in regulation of innate lymphoid cells: The gods before the guardians

(2018) Helena Stabile et al.   IMMUNOLOGICAL REVIEWS

The natural polyphenol curcumin induces apoptosis by suppressing STAT3 signaling in esophageal squamous cell carcinoma

(2018) Ying Liu et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Anti-cancer Therapies Employing IL-2 Cytokine Tumor Targeting: Contribution of Innate, Adaptive and Immunosuppressive Cells in the Anti-tumor Efficacy

(2018) Lorenzo Mortara et al.   Frontiers in Immunology

Protein Inhibitor of Activated STAT (PIAS) Negatively Regulates the JAK/STAT Pathway by Inhibiting STAT Phosphorylation and Translocation

(2018) Guo-Juan Niu et al.   Frontiers in Immunology

Trial Watch: Toll-like receptor agonists in cancer immunotherapy

(2018) Melody Smith et al.   OncoImmunology

STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial

(2018) Matthew J. Reilley et al.   Journal for ImmunoTherapy of Cancer

Expression of STAT3 in Prostate Cancer Metastases

(2017) Nicholas Don-Doncow et al.   EUROPEAN UROLOGY

The molecular basis for differential type I interferon signaling

(2017) Gideon Schreiber   JOURNAL OF BIOLOGICAL CHEMISTRY

Unphosphorylated STAT1 represses apoptosis in macrophages duringMycobacteriumtuberculosisinfection

(2017) Kezhen Yao et al.   JOURNAL OF CELL SCIENCE

JAK/STAT disruption induces immuno-deficiency: Rationale for the development of JAK inhibitors as immunosuppressive drugs

(2017) Isabelle Cornez et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Jak Stat signaling and cancer: Opportunities, benefits and side effects of targeted inhibition

(2017) Bernd Groner et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Unphosphorylated ISGF3 drives constitutive expression of interferon-stimulated genes to protect against viral infections

(2017) Wenshi Wang et al.   Science Signaling

MiR-629 promotes human pancreatic cancer progression by targeting FOXO3

(2017) Haijiao Yan et al.   Cell Death & Disease

Interferon-γ derived from cytotoxic lymphocytes directly enhances their motility and cytotoxicity

(2017) Purnima Bhat et al.   Cell Death & Disease

IFN-γ is required for cytotoxic T cell-dependent cancer genome immunoediting

(2017) Kazuyoshi Takeda et al.   Nature Communications

Cancer gene profiling in non-small cell lung cancers reveals activating mutations in JAK2 and JAK3 with therapeutic implications

(2017) Shuyu D. Li et al.   Genome Medicine

Unphosphorylated ISGF3 drives constitutive expression of interferon-stimulated genes to protect against viral infections

(2017) Wenshi Wang et al.   Science Signaling

Neoadjuvant Interferons: Critical for Effective PD-1–Based Immunotherapy in TNBC

(2017) Natasha K. Brockwell et al.   Cancer Immunology Research

Myeloid STAT3 Promotes Lung Tumorigenesis by Transforming Tumor Immunosurveillance into Tumor-Promoting Inflammation

(2017) Jingjiao Zhou et al.   Cancer Immunology Research

Dysregulation of SOCS-Mediated Negative Feedback of Cytokine Signaling in Carcinogenesis and Its Significance in Cancer Treatment

(2017) Mengmeng Jiang et al.   Frontiers in Immunology

STATs in NK-Cells: The Good, the Bad, and the Ugly

(2017) Dagmar Gotthardt et al.   Frontiers in Immunology

Targeting cytokine signaling checkpoint CIS activates NK cells to protect from tumor initiation and metastasis

(2017) Eva M. Putz et al.   OncoImmunology

Loss of function JAK1 mutations occur at high frequency in cancers with microsatellite instability and are suggestive of immune evasion

(2017) Lee A. Albacker et al.   PLoS One

High incidence of activating STAT5B mutations in CD4-positive T-cell large granular lymphocyte leukemia

(2016) E. I. Andersson et al.   BLOOD

A Breakthrough: Macrophage-Directed Cancer Immunotherapy

(2016) C. D. Mills et al.   CANCER RESEARCH

The urgent need to recover MHC class I in cancers for effective immunotherapy

(2016) Federico Garrido et al.   CURRENT OPINION IN IMMUNOLOGY

JAK-STAT signaling in cancer: From cytokines to non-coding genome

(2016) Jan Pencik et al.   CYTOKINE

Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations

(2016) Daniel Sanghoon Shin et al.   Cancer Discovery

Curcumin Suppressed Activation of Dendritic Cells via JAK/STAT/SOCS Signal in Mice with Experimental Colitis

(2016) Hai-Mei Zhao et al.   Frontiers in Pharmacology

The long noncoding RNA CASC2 functions as a competing endogenous RNA by sponging miR-18a in colorectal cancer

(2016) Guanli Huang et al.   Scientific Reports

The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours

(2015) S J Thomas et al.   BRITISH JOURNAL OF CANCER

Beyond the histone tale: HP1α deregulation in breast cancer epigenetics

(2015) Johan Vad-Nielsen et al.   CANCER BIOLOGY & THERAPY

Cyclooxygenase-2 promotes tumor growth and suppresses tumor immunity

(2015) Bing Liu et al.   Cancer Cell International

The paradoxical role of IL-10 in immunity and cancer

(2015) Mark H. Mannino et al.   CANCER LETTERS

STAT3 Establishes an Immunosuppressive Microenvironment during the Early Stages of Breast Carcinogenesis to Promote Tumor Growth and Metastasis

(2015) Laura M. Jones et al.   CANCER RESEARCH

Interleukin-15: New kid on the block for antitumor combination therapy

(2015) Johan M.J. Van den Bergh et al.   CYTOKINE & GROWTH FACTOR REVIEWS

Understanding the Mechanisms of Androgen Deprivation Resistance in Prostate Cancer at the Molecular Level

(2015) Theodoros Karantanos et al.   EUROPEAN UROLOGY

TCR and CD28 activate the transcription factor NF-κB in T-cells via distinct adaptor signaling complexes

(2015) Youg Raj Thaker et al.   IMMUNOLOGY LETTERS

Constitutive activation of STAT3 in breast cancer cells: A review

(2015) Kasturi Banerjee et al.   INTERNATIONAL JOURNAL OF CANCER

Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed

(2015) Herbert I. Hurwitz et al.   JOURNAL OF CLINICAL ONCOLOGY

Cish actively silences TCR signaling in CD8 + T cells to maintain tumor tolerance

(2015) Douglas C. Palmer et al.   JOURNAL OF EXPERIMENTAL MEDICINE

IL-10 Potentiates Differentiation of Human Induced Regulatory T Cells via STAT3 and Foxo1

(2015) Peter Hsu et al.   JOURNAL OF IMMUNOLOGY

PIAS1 is a determinant of poor survival and acts as a positive feedback regulator of AR signaling through enhanced AR stabilization in prostate cancer

(2015) M Puhr et al.   ONCOGENE

NK cells regulating T cell responses: mechanisms and outcome

(2015) Josh Crouse et al.   TRENDS IN IMMUNOLOGY

ICAM-1 suppresses tumor metastasis by inhibiting macrophage M2 polarization through blockade of efferocytosis

(2015) M Yang et al.   Cell Death & Disease

Siltuximab (CNTO 328): a promising option for human malignancies

(2015) Bao-An Chen et al.   Drug Design Development and Therapy

STAT1 deficiency redirects IFN signalling toward suppression of TLR response through a feedback activation of STAT3

(2015) Hun Sik Kim et al.   Scientific Reports

Loss of Host Type-I IFN Signaling Accelerates Metastasis and Impairs NK-cell Antitumor Function in Multiple Models of Breast Cancer

(2015) J. Rautela et al.   Cancer Immunology Research

Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy

(2015) Kristina Iribarren et al.   OncoImmunology

Serum IL-10 Predicts Worse Outcome in Cancer Patients: A Meta-Analysis

(2015) Shuai Zhao et al.   PLoS One

Putting the brakes on mammary tumorigenesis: Loss of STAT1 predisposes to intraepithelial neoplasias

(2015) Christine Schneckenleithner et al.   Oncotarget

Loss of STAT1 from Mouse Mammary Epithelium Results in an Increased Neu-Induced Tumor Burden

(2015) Peter J. Klover et al.   NEOPLASIA

High STAT1 mRNA levels but not its tyrosine phosphorylation are associated with macrophage infiltration and bad prognosis in breast cancer

(2014) Piotr Tymoszuk et al.   BMC CANCER

Drug Resistance via Feedback Activation of Stat3 in Oncogene-Addicted Cancer Cells

(2014) Ho-June Lee et al.   CANCER CELL

IFN-γ regulates survival and function of tumor-induced CD11b+Gr-1highmyeloid derived suppressor cells by modulating the anti-apoptotic molecule Bcl2a1

(2014) José Medina-Echeverz et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

IL-2: The First Effective Immunotherapy for Human Cancer

(2014) S. A. Rosenberg   JOURNAL OF IMMUNOLOGY

New Function of Type I IFN: Induction of Autophagy

(2014) Hana Schmeisser et al.   JOURNAL OF INTERFERON AND CYTOKINE RESEARCH

Upregulation of Stat1-HDAC4 confers resistance to etoposide through enhanced multidrug resistance 1 expression in human A549 lung cancer cells

(2014) CHUTIMA KAEWPIBOON et al.   Molecular Medicine Reports

Immune Cell-Poor Melanomas Benefit from PD-1 Blockade after Targeted Type I IFN Activation

(2014) T. Bald et al.   Cancer Discovery

Type I Interferons as Regulators of Human Antigen Presenting Cell Functions

(2014) Sandra Gessani et al.   Toxins

IL-10: Master Switch from Tumor-Promoting Inflammation to Antitumor Immunity

(2014) M. Oft   Cancer Immunology Research

STAT3 in Cancer—Friend or Foe?

(2014) Hai-Feng Zhang et al.   Cancers

Crosstalk between the Type 1 Interferon and Nuclear Factor Kappa B Pathways Confers Resistance to a Lethal Virus Infection

(2013) Daniel Rubio et al.   Cell Host & Microbe

NF-κB: roles and regulation in different CD4+T-cell subsets

(2013) Hyunju Oh et al.   IMMUNOLOGICAL REVIEWS

Tumor STAT1 Transcription Factor Activity Enhances Breast Tumor Growth and Immune Suppression Mediated by Myeloid-derived Suppressor Cells

(2013) Laura M. Hix et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Interferon-dependent IL-10 production by Tregs limits tumor Th17 inflammation

(2013) C. Andrew Stewart et al.   JOURNAL OF CLINICAL INVESTIGATION

STAT inhibitors for cancer therapy

(2013) Muhammad Furqan et al.   Journal of Hematology & Oncology

TLR agonists: our best frenemy in cancer immunotherapy

(2013) Sabina Kaczanowska et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Distinct roles of STAT3 and STAT5 in the pathogenesis and targeted therapy of breast cancer

(2013) Sarah R. Walker et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

T-helper-1-cell cytokines drive cancer into senescence

(2013) Heidi Braumüller et al.   NATURE

A new look at T cell receptor signaling to nuclear factor-κB

(2013) Suman Paul et al.   TRENDS IN IMMUNOLOGY

A novel STAT inhibitor, OPB-31121, has a significant antitumor effect on leukemia with STAT-addictive oncokinases

(2013) F Hayakawa et al.   Blood Cancer Journal

CDK8-Mediated STAT1-S727 Phosphorylation Restrains NK Cell Cytotoxicity and Tumor Surveillance

(2013) Eva Maria Putz et al.   Cell Reports

NKG2D ligand tumor expression and association with clinical outcome in early breast cancer patients: an observational study

(2012) Esther M de Kruijf et al.   BMC CANCER

JAK2/STAT5 Inhibition Circumvents Resistance to PI3K/mTOR Blockade: A Rationale for Cotargeting These Pathways in Metastatic Breast Cancer

(2012) Adrian Britschgi et al.   CANCER CELL

S1PR1-STAT3 Signaling Is Crucial for Myeloid Cell Colonization at Future Metastatic Sites

(2012) Jiehui Deng et al.   CANCER CELL

Interferon-γ-induced activation of Signal Transducer and Activator of Transcription 1 (STAT1) up-regulates the tumor suppressing microRNA-29 family in melanoma cells

(2012) Martina J Schmitt et al.   Cell Communication and Signaling

Molecular Pathways: Interferon/Stat1 Pathway: Role in the Tumor Resistance to Genotoxic Stress and Aggressive Growth

(2012) N. N. Khodarev et al.   CLINICAL CANCER RESEARCH

Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease

(2012) Apostolos Kontzias et al.   CURRENT OPINION IN PHARMACOLOGY

Biology and significance of the JAK/STAT signalling pathways

(2012) Hiu Kiu et al.   GROWTH FACTORS

IL-6 Trans-Signaling via the Soluble IL-6 Receptor: Importance for the Pro-Inflammatory Activities of IL-6

(2012) Stefan Rose-John   International Journal of Biological Sciences

STAT3 mutations are highly specific for large granular lymphocytic leukemia

(2012) A Fasan et al.   LEUKEMIA

Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape

(2012) Bradley N Bidwell et al.   NATURE MEDICINE

SomaticSTAT3Mutations in Large Granular Lymphocytic Leukemia

(2012) Hanna L.M. Koskela et al.   NEW ENGLAND JOURNAL OF MEDICINE

Type I interferon response and innate immune sensing of cancer

(2012) Mercedes B. Fuertes et al.   TRENDS IN IMMUNOLOGY

Silencing of microRNA-122 enhances interferon-α signaling in the liver through regulating SOCS3 promoter methylation

(2012) Takeshi Yoshikawa et al.   Scientific Reports

IL-15 and Type I Interferon Are Required for Activation of Tumoricidal NK Cells by Virus-Infected Dendritic Cells

(2011) J. E. Boudreau et al.   CANCER RESEARCH

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Direct Effects of Type I Interferons on Cells of the Immune System

(2011) S. Hervas-Stubbs et al.   CLINICAL CANCER RESEARCH

JAKs go nuclear: Emerging role of nuclear JAK1 and JAK2 in gene expression and cell growth

(2011) Fouad A. Zouein et al.   GROWTH FACTORS

The JAK2/STAT3 signaling pathway is required for growth of CD44+CD24– stem cell–like breast cancer cells in human tumors

(2011) Lauren L.C. Marotta et al.   JOURNAL OF CLINICAL INVESTIGATION

Host type I IFN signals are required for antitumor CD8+T cell responses through CD8α+dendritic cells

(2011) Mercedes B. Fuertes et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Epigenetic repression of the Igk locus by STAT5-mediated recruitment of the histone methyltransferase Ezh2

(2011) Malay Mandal et al.   NATURE IMMUNOLOGY

Cytokines in Cancer Immunotherapy

(2011) Sylvia Lee et al.   Cancers

microRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma

(2010) J.-J. Zhao et al.   BLOOD

IL-6 Trans-Signaling in Formation and Progression of Malignant Ascites in Ovarian Cancer

(2010) Chi-Wen Lo et al.   CANCER RESEARCH

MicroRNA-155 Functions as an OncomiR in Breast Cancer by Targeting the Suppressor of Cytokine Signaling 1 Gene

(2010) S. Jiang et al.   CANCER RESEARCH

The JAK2 V617F somatic mutation, mortality and cancer risk in the general population

(2010) C. Nielsen et al.   HAEMATOLOGICA

Functional Crosstalk between Type I and II Interferon through the Regulated Expression of STAT1

(2010) Daniel J. Gough et al.   PLOS BIOLOGY

The JAK2 Inhibitor AZD1480 Potently Blocks Stat3 Signaling and Oncogenesis in Solid Tumors

(2009) Michael Hedvat et al.   CANCER CELL

IL-6 and Stat3 Are Required for Survival of Intestinal Epithelial Cells and Development of Colitis-Associated Cancer

(2009) Sergei Grivennikov et al.   CANCER CELL

Reduced Risk of Bone Metastasis for Patients With Breast Cancer Who Use COX-2 Inhibitors

(2009) Matias E. Valsecchi et al.   Clinical Breast Cancer

Cross-regulation of Signaling Pathways by Interferon-γ: Implications for Immune Responses and Autoimmune Diseases

(2009) Xiaoyu Hu et al.   IMMUNITY

The contribution of direct TLR signaling to T cell responses

(2009) Adeeb H. Rahman et al.   IMMUNOLOGIC RESEARCH

Akt-mediated regulation of NFκB and the essentialness of NFκB for the oncogenicity of PI3K and Akt

(2009) Dong Bai et al.   INTERNATIONAL JOURNAL OF CANCER

Primary Human Tumor Cells Expressing CD155 Impair Tumor Targeting by Down-Regulating DNAM-1 on NK Cells

(2009) M. Carlsten et al.   JOURNAL OF IMMUNOLOGY

Interferon Regulatory Factors in Hematopoietic Cell Differentiation and Immune Regulation

(2009) Angela Battistini   JOURNAL OF INTERFERON AND CYTOKINE RESEARCH

JAK2 phosphorylates histone H3Y41 and excludes HP1α from chromatin

(2009) Mark A. Dawson et al.   NATURE

Unphosphorylated STAT1 prolongs the expression of interferon-induced immune regulatory genes

(2009) H. Cheon et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Roles of the NF- B Pathway in Lymphocyte Development and Function

(2009) S. Gerondakis et al.   Cold Spring Harbor Perspectives in Biology

Somatic Mutations of JAK1 and JAK3 in Acute Leukemias and Solid Cancers

(2008) E. G. Jeong et al.   CLINICAL CANCER RESEARCH

Toll-like receptor 9 (TLR9) agonists in the treatment of cancer

(2008) A M Krieg   ONCOGENE

An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer

(2008) R. R. Weichselbaum et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA